LINC02880: A Long Intergenic Non-Protein Coding RNA (G285759)

Target Name: LINC02880

NCBI ID: G285759

LINC02880

Other Name(s): long intergenic non-protein coding RNA 2880 | Long intergenic non-protein coding RNA 2880

LINC02880: A Long Intergenic Non-Protein Coding RNA

LINC02880 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its ability to interact with protein-coding genes and its involvement in various cellular processes. LINC02880 has been shown to play a critical role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, LINC02880 has gained significant interest as a potential drug target or biomarker.

Expression and Localization

LINC02880 is a highly expressed gene in most organisms, including humans. It is expressed in various tissues, including brain, heart, and muscle, and has been shown to localize to specific cellular compartments, such as the nuclear envelope and the endoplasmic reticulum.

Function and Interaction with Proteins

LINC02880 is known for its ability to interact with various proteins, including known drug targets, such as tyrosine kinase receptor 2 (TKR2) and heat shock protein 70 (Hsp70). These interactions result in the regulation of various cellular processes, including cell growth, apoptosis, and transcriptional regulation.

Disease association

LINC02880 has been strongly associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, LINC02880 has been shown to be highly expressed in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and has been implicated in the development of these conditions. Additionally, LINC02880 has been associated with cancer, where it has been shown to be regulated by various oncogenic factors.

Drug targeting

LINC02880 has been identified as a potential drug target due to its involvement in various cellular processes and its ability to interact with known drug targets. One approach to targeting LINC02880 is to use small molecules or antibodies that can interact with its known interactors, such as TKR2 and Hsp70.

Antibodies against LINC02880 have been shown to be effective in animal models of cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, small molecules that can interact with LINC02880 have been shown to be effective in cell-based assays of drug targeting.

Biomarker potential

LINC02880 has the potential to serve as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression has been shown to be regulated by various factors, including disease-specific genetic and environmental factors. As a result, LINC02880 has the potential to serve as a biomarker for personalized medicine, where therapeutic approaches can be tailored to specific individual genetic profiles.

Conclusion

LINC02880 is a long non-coding RNA that has been identified in various organisms and has been shown to play a critical role in the development and progression of various diseases. Its expression and interaction with known proteins make it a potential drug target or biomarker. Further research is needed to fully understand the role of LINC02880 in disease progression and to develop effective therapies that can target this RNA.

Protein Name: Long Intergenic Non-protein Coding RNA 2880

The "LINC02880 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02880 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets